Lung Therapeutics

Lung Therapeutics

Lung Therapeutics is a therapeutics for lung injury and disease company founded in 2013 by Andrew Mazar, Steven Idell and Sreerama Shetty.

Lung Therapeutics is a privately held, clinical stage pharmaceutical company based in Austin, Texas that was founded in 2013 by Andrew Mazar and Steven Idell. It's pursues orphan drug indications for lung injury and disease due to fibrosis for which there are no effective non-surgical options.

Products

The company has two lead product candidates in its pipeline, LTI-01 and LTI-03. They focus on loculated plural effusion and idiopathic pulmonary fibrosis, respectively.

LTI-01

LTI-01 is an injectable, fibrinolytic drug that maximizes scar removal around the lung and thereby promotes fluid drainage while minimizing bleeding risk and other complications. Its active pharmaceutical ingredient is a proenzyme, or zymogen, which slowly becomes activated in the pleural space surrounding the lungs. LTI-01 has received orphan drug designation from both the FDA (2014) and the European Commission (2015) for the treatment of empyema. Phase 1B clinical trials are being conducted at three sites in Australia and New Zealand.

LTI-03

LTI-03 is a drug product that addresses Idiopathic Pulmonary Fibrosis. It is in preclinical development and has shown to resolve bleomycin-induced lung injury. It also has the potential to restore healthy lung function in patients suffering from the disease. In addition, LTI-03 has shown promise in other models of fibrotic diseases.

Funding

Series A

On September 30, 2015 Lung Therapeutics completed their series A funding with $2.6 million in funding from UT Horizon Fund.

Series B

On June 6, 2017 Lung Therapeutics completed their series B funding round with $14.3 million in funding from Bios Partners (lead investor) and UT Horizon Fund.

Timeline

June 2017

Lung Therapeutics raises a $14,300,000 series B round from UT Horizon Fund and Bios Partners.

2013

Lung Therapeutics was founded by Andrew Mazar, Steven Idell and Sreerama Shetty.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Andrew Mazar

Founder & Head of Product Development

Brian Windsor

CEO

John J. Koleng

VP CMC - Inhalation Products

Stevel Idell

Founder & Chief Scientific Officer

Further reading

Title
Author
Link
Type
Date

Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand

Lung Therapeutics, Inc.

Web

Pharma Start-up Lung Therapeutics, Inc. Achieves Significant Funding to Address Unmet Needs in Lung Injury and Disease

Lung Therapeutics, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.